Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Percheron Therapeutics Limited ABN/ARBN Financial year ended: 41095060745 30 June...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Appendix 4E and Annual Report
- Application for quotation of securities - PER
- Notice of date of AGM and other relevant dates
- Percheron Therapeutics Announces CEO Succession
- Quarterly Activities Report and Appendix 4C
Later from Percheron Therapeutics
- Vanderbilt Health to conduct clinical trial of HMBD-002
- Trading Halt
- Percheron receives $0.70m R&D Tax Incentive Rebate
- Notification of cessation of securities - PER
- Change of Director's Interest Notice
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics